BioCentury
ARTICLE | Company News

Celltrion wins another biosimilar infliximab lawsuit

August 3, 2018 5:51 PM UTC

A federal judge ruled July 30 that biosimilar Inflectra infliximab-dyyb from Celltrion Inc. (KOSDAQ:068270) does not infringe a patent from Johnson & Johnson (NYSE:JNJ) covering autoimmune drug Remicade infliximab. The decision follows a previous Celltrion victory invalidating another Remicade patent.

The ruling involved J&J's U.S. Patent No. 7,598,083, which claims cell culture media compositions used to produce infliximab. District Judge Mark Wolf held that while media used by Celltrion to produce Inflectra contains several ingredients claimed in the '083 patent, a person of ordinary skill would have been able to combine familiar ingredients from prior art to create what Janssen claims as its invention...